Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy

ConditionsStroke Acute Ischemic Stroke

Trial statusNot yet recruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine

About this trial

To screen ischemic stroke patients likely to benefit from anticoagulation and compare the effectiveness and safety of anticoagulation versus antiplatelet therapy in preventing recurrent ischemic stroke within 3 months.

Eligibility criteria

Qualifiers

Age ≥18 years

Ischemic stroke patients with undetermined etiology, within 14 days of onset, with completed etiological assessment

Cortical or multi-territorial infarct

Recurrent stroke or stroke on antiplatelet therapy

Disqualifiers

Stenosis ≥50% in the responsible vessel or high-risk plaque

Identified cardioembolic source

PFO with planned closure

Malignancy

Trial design

Treatments tested in this trial

Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran
Aspirin

Treatment groups

680 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Second Affiliated Hospital, Zhejiang University, School of Medicine

Lead sponsor

Source ClinicalTrials.gov